Financials in USD. Standardized financial statements.
A compact view of how Lyell Immunopharma, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Revenue? | $36,000 | $61,000 | $130,000 | $84.68M | $10.65M | $7.76M | $657,000 |
| Revenue Growth? | -41.0% | -53.1% | -99.8% | +695.1% | +37.3% | +1080.5% | 0.0% |
| Cost of Revenue? | $11.54M | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Profit? | -$11.50M | $61,000 | $130,000 | $84.68M | $10.65M | $7.76M | $657,000 |
| Gross Margin? | -31952.8% | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% |
| Operating Expenses? | $192.27M | $358.82M | $247.14M | $271.74M | $225.43M | $219.69M | $102.75M |
| Operating Income? | -$203.77M | -$358.75M | -$247.01M | -$187.06M | -$214.78M | -$211.94M | -$102.09M |
| EBITDA? | -$192.24M | -$200.64M | -$226.76M | -$169.04M | -$201.15M | -$215.43M | -$100.83M |
| Income Before Tax | -$274.45M | -$342.99M | -$234.63M | -$183.12M | -$250.22M | -$204.47M | -$129.38M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income? | -$274.45M | -$342.99M | -$234.63M | -$183.12M | -$250.22M | -$204.47M | -$129.38M |
| EPS? | $-16.06 | $-1.31 | $-0.93 | $-0.74 | $-1.03 | $-0.84 | $-0.53 |
| Diluted EPS? | $-16.06 | $-1.31 | $-0.93 | $-0.74 | $-1.03 | $-0.84 | $-0.53 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality